Literature DB >> 28714740

Do STAT3 inhibitors have potential in the future for cancer therapy?

Andrea L A Wong1,2,3, Jayshree L Hirpara3, Shazib Pervaiz4,5, Jie-Qing Eu3, Gautam Sethi6, Boon-Cher Goh1,2,3,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28714740     DOI： 10.1080/13543784.2017.1351941

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


× No keyword cloud information.
  87 in total

1.  Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics.

Authors:  Jennifer M Speth; Loka R Penke; Joseph D Bazzill; Kyung Soo Park; Rafael Gil de Rubio; Daniel J Schneider; Hideyasu Ouchi; James J Moon; Venkateshwar G Keshamouni; Rachel L Zemans; Vibha N Lama; Douglas A Arenberg; Marc Peters-Golden
Journal:  JCI Insight       Date:  2019-10-17

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

3.  My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.

Authors:  Alexander Levitzki; Shoshana Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-10       Impact factor: 11.205

4.  A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3.

Authors:  Xiaofei Shen; Lin Zhao; Peihao Chen; Yanqiu Gong; Dingdong Liu; Xia Zhang; Lunzhi Dai; Qingxiang Sun; Jizhong Lou; Zhong Jin; Baohua Zhang; Dawen Niu; Ceshi Chen; Xiangbing Qi; Da Jia
Journal:  J Biol Chem       Date:  2019-10-08       Impact factor: 5.157

5.  27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.

Authors:  Shweta Dambal; Mahmoud Alfaqih; Sergio Sanders; Erick Maravilla; Adela Ramirez-Torres; Gloria C Galvan; Mariana Reis-Sobreiro; Mirja Rotinen; Lucy M Driver; Matthew S Behrove; Tijana Jovanovic Talisman; Junhee Yoon; Sungyong You; James Turkson; Jen-Tsan Chi; Michael R Freeman; Everardo Macias; Stephen J Freedland
Journal:  Mol Cancer Res       Date:  2020-02-04       Impact factor: 5.852

Review 6.  Plasticity of Cancer Stem Cell: Origin and Role in Disease Progression and Therapy Resistance.

Authors:  Plabon Kumar Das; Suja Pillai; Md Abdur Rakib; Jahan Ara Khanam; Vinod Gopalan; Alfred K Y Lam; Farhadul Islam
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

7.  A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.

Authors:  Longchuan Bai; Haibin Zhou; Renqi Xu; Yujun Zhao; Krishnapriya Chinnaswamy; Donna McEachern; Jianyong Chen; Chao-Yie Yang; Zhaomin Liu; Mi Wang; Liu Liu; Hui Jiang; Bo Wen; Praveen Kumar; Jennifer L Meagher; Duxin Sun; Jeanne A Stuckey; Shaomeng Wang
Journal:  Cancer Cell       Date:  2019-11-11       Impact factor: 31.743

8.  Deficiency of tumor suppressor Merlin facilitates metabolic adaptation by co-operative engagement of SMAD-Hippo signaling in breast cancer.

Authors:  Mateus S V Mota; William P Jackson; Sarah K Bailey; Praveen Vayalil; Aimee Landar; Jack W Rostas; Madhuri S Mulekar; Rajeev S Samant; Lalita A Shevde
Journal:  Carcinogenesis       Date:  2018-09-21       Impact factor: 4.944

9.  Betacellulin drives therapy resistance in glioblastoma.

Authors:  Qiwen Fan; Zhenyi An; Robyn A Wong; Xujun Luo; Edbert D Lu; Albert Baldwin; Manasi K Mayekar; Franziska Haderk; Kevan M Shokat; Trever G Bivona; William A Weiss
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

10.  Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy.

Authors:  Masahiro Shibata; Akira Ooki; Yoshikuni Inokawa; Pritam Sadhukhan; M Talha Ugurlu; Evgeny Izumchenko; Enrico Munari; Giuseppe Bogina; Charles M Rudin; Edward Gabrielson; Anju Singh; Mohammad O Hoque
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.